Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Interesting things happening
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(197)
•••
Comment by Maui527on Feb 08, 2021 10:16pm
296 Views
Post# 32509027

RE:Interesting things happening

RE:Interesting things happeningWOW...This makes so much sense!!!

Could the lenghthy delay in getting unhalted be a strategy??? A startegy to position the company for a new beginning with NO??? I strongly believe that there is so much more than the obvious to this story! Robert has too much online to just have this sewer!

In speaking to Robert today, his comments around the US shares trading, was that they could, and anyone in the know is dfrving this up to $0.10 US!! This makes so much sense!

There was a time where I had writen off my shares (and I own a large chuck) but now I cannot wait to open and hold!

I am very familiar with the SaNOtize prodcut, read and watch the full review on it! It is brilliant!!! Not only would it significantly benit COVID recivery, but there are more benfits that the prodcut has to offer!

Here is link for some DD...https://sanotize.com/

Then next week should get real interesting!!!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities